BriaCell's BriaPro subsidiary posts Q1 loss of $128K; holds $211K in intangible assets

BriaCell Therapeutics Corp.

BriaPro completed spin-out from BriaCell on Aug 31, 2023, receiving Bria-TILsRx and PKCδ inhibitor assets.
Net loss of $128K for three months ended Oct 31, 2023; no revenue; operating loss $132K.
Intangible assets (patents) of $211K net; cash and equivalents of $1; accumulated deficit $148K.
Going concern uncertainty noted; BriaPro needs additional financing to continue operations.
BriaCell owns 2/3 of BriaPro; provides transition services for $20K/month.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.